Remission Alliance RGB While a cure for CML remains the ultimate goal, treatment free remission (TFR) is often the treatment target for those on TKI therapy. Still, with around 50-60% of people achieving sustained TFR there is much room for improvement.
The iCMLf TFR Alliance has now evolved into a global network of 41 collaborators from 21 countries aiming to enhance successful TFR attempts for people with CML.

In 2021 the TFR Alliance began the process to establish an International TFR Registry that will be an optimal way to study clinically (and pharmaco-economically) important research questions on treatment-free remission.

To set up the registry, initial seed funding from the iCMLf was awarded to the Swedish CML Registry Group following a call for proposals. In August, a first meeting was held to define priorities for the TFR Registry and a survey to define the registry parameters and outcomes was sent out to the community. We meet in February to finalise the registry priorities and move into set up phase.

Learn more about the TFR Registry and how to get involved...

January 2022 - Great progress has been made in CML over the past decades, but scientists and clinicians around the world continue to work hard to develop new therapies and treatment strategies for patients globally with the ultimate aim to find a cure for CML.

We continue with our tradition to recognise individuals who have played a major role in advancing our understanding of the biology of CML and to improving the management of CML. Ultimately, it’s personal commitment, passion and tireless work that drives research and makes a difference for people with CML.

Since the first iCMLf Rowley Prize was awarded to Professor Brian Druker in 2009, we have honoured 29 scientists and clinicians with the three specific iCMLf Prizes.

Who would you like to see awarded the iCMLf prizes this year?

December 2021 - From all of us at the iCMLf we wish you a safe healthy and happy holiday season.

As another eventful year comes to an end we would like to take the opportunity to reflect on our work and thank you for your support for the Foundation’s activities and programs over the last 12 months.

It’s people working together that make the CML community so unique, and we thank all our funders, partners and supporters.

We with you the very best greetings of the season and are looking forward to working with and for you, in the New Year.

It is with great sadness that we share the news of the death of Professor Michele Baccarani. A friend and colleague to so many in the CML community and beyond, we share our thoughts and condolences to all who knew him.

We share the sorrow of losing another giant in CML research, education and patient care. The CML community has lost one of its most influential leaders and I personally have lost a teacher and friend. His thoughtful discussions and scholar contributions influenced many in the scientific community and challenged us to always aim for better outcomes for our CML patients. – Professor Jorge Cortes, Director Georgia Cancer Centre, USA

December 2021 - We are delighted that the iCMLf CML and COVID-19 (CANDID data) was presented at the 63^rd Annual Meeting of the American Society of Hematology (ASH) this week. The iCMLf CANDID study represents the largest global cohort study of CML patients with COVID-19 aiming to collect and analyse characteristics of COVID-19 cases among CML patients globally. During ASH, Dr Katia Pagnano presented an update of the CANDID data that explored the impact of various risk factors, such as co-morbidities, age, disease phase, CML treatment and economic status of the country of origin on clinical outcomes.

The CANDID real world data collection with more than 1,000 cases from 59 countries would not have been possible without the 186 physicians who contributed case reports. We thank everybody for their valuable contributions.

If you are looking for more ASH news, join us for the live CML highlights with Professor Susan Branford and Associate Professor Charles Chuah on December 23 at 13.00 Central European Time. (More details below)

November 2021 - We continue our 'From the laboratory' series on the iCMLf Knowledge Centre with a new module for clinicians that will increase your knowledge on diagnosis and testing methods.

Module 4 is a series of talks that will take you on the journey with your patients from diagnosis to monitoring response and the role of genomic mutation screening. Starting with the main laboratory studies at diagnosis, you’ll then learn how to best monitor your patients over time and what are the critical milestones.

Other presentations will give an overview of mutation testing in case of relapse or resistance, how to interpret results and what to do clinically when your patients have certain mutations. Another presentation focuses on mutations other than BCR-ABL, how often they occur and conclusions for clinical practice.

As always, we have put a spotlight on the needs of physicians treating CML patients in the emerging regions, specifically solutions for diagnosis and testing in a resource-constrained setting.

Learn more in a short video overview from Professor Jerry Radich, who co-chairs this module together with Dr Carolina Pavlovsky from Argentina.

Page 20 of 44

Copyright © 2023 All Rights Reserved. The iCMLf is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK